FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118771330> ?p ?o ?g. }

• W2118771330 endingPage "232" @default.
• W2118771330 startingPage "223" @default.
• W2118771330 abstract "Background Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens. Methods In a phase III, international, multicentre, controlled, parallel-group, open-label trial, patients with higher-risk myelodysplastic syndromes were randomly assigned one-to-one to receive azacitidine (75 mg/m2 per day for 7 days every 28 days) or conventional care (best supportive care, low-dose cytarabine, or intensive chemotherapy as selected by investigators before randomisation). Patients were stratified by French–American–British and international prognostic scoring system classifications; randomisation was done with a block size of four. The primary endpoint was overall survival. Efficacy analyses were by intention to treat for all patients assigned to receive treatment. This study is registered with ClinicalTrials.gov, number NCT00071799. Findings Between Feb 13, 2004, and Aug 7, 2006, 358 patients were randomly assigned to receive azacitidine (n=179) or conventional care regimens (n=179). Four patients in the azacitidine and 14 in the conventional care groups received no study drugs but were included in the intention-to-treat efficacy analysis. After a median follow-up of 21·1 months (IQR 15·1–26·9), median overall survival was 24·5 months (9·9–not reached) for the azacitidine group versus 15·0 months (5·6–24·1) for the conventional care group (hazard ratio 0·58; 95% CI 0·43–0·77; stratified log-rank p=0·0001). At last follow-up, 82 patients in the azacitidine group had died compared with 113 in the conventional care group. At 2 years, on the basis of Kaplan-Meier estimates, 50·8% (95% CI 42·1–58·8) of patients in the azacitidine group were alive compared with 26·2% (18·7–34·3) in the conventional care group (p<0·0001). Peripheral cytopenias were the most common grade 3–4 adverse events for all treatments. Interpretation Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care. Funding Celgene Corporation. Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens. In a phase III, international, multicentre, controlled, parallel-group, open-label trial, patients with higher-risk myelodysplastic syndromes were randomly assigned one-to-one to receive azacitidine (75 mg/m2 per day for 7 days every 28 days) or conventional care (best supportive care, low-dose cytarabine, or intensive chemotherapy as selected by investigators before randomisation). Patients were stratified by French–American–British and international prognostic scoring system classifications; randomisation was done with a block size of four. The primary endpoint was overall survival. Efficacy analyses were by intention to treat for all patients assigned to receive treatment. This study is registered with ClinicalTrials.gov, number NCT00071799. Between Feb 13, 2004, and Aug 7, 2006, 358 patients were randomly assigned to receive azacitidine (n=179) or conventional care regimens (n=179). Four patients in the azacitidine and 14 in the conventional care groups received no study drugs but were included in the intention-to-treat efficacy analysis. After a median follow-up of 21·1 months (IQR 15·1–26·9), median overall survival was 24·5 months (9·9–not reached) for the azacitidine group versus 15·0 months (5·6–24·1) for the conventional care group (hazard ratio 0·58; 95% CI 0·43–0·77; stratified log-rank p=0·0001). At last follow-up, 82 patients in the azacitidine group had died compared with 113 in the conventional care group. At 2 years, on the basis of Kaplan-Meier estimates, 50·8% (95% CI 42·1–58·8) of patients in the azacitidine group were alive compared with 26·2% (18·7–34·3) in the conventional care group (p<0·0001). Peripheral cytopenias were the most common grade 3–4 adverse events for all treatments. Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care." @default.
• W2118771330 created "2016-06-24" @default.
• W2118771330 creator A5000921376 @default.
• W2118771330 creator A5014838075 @default.
• W2118771330 creator A5015991333 @default.
• W2118771330 creator A5031248010 @default.
• W2118771330 creator A5032585809 @default.
• W2118771330 creator A5040454560 @default.
• W2118771330 creator A5042018798 @default.
• W2118771330 creator A5042020284 @default.
• W2118771330 creator A5043227502 @default.
• W2118771330 creator A5046816795 @default.
• W2118771330 creator A5052920087 @default.
• W2118771330 creator A5053367608 @default.
• W2118771330 creator A5063557220 @default.
• W2118771330 creator A5065716888 @default.
• W2118771330 creator A5065804627 @default.
• W2118771330 creator A5070851212 @default.
• W2118771330 creator A5071026405 @default.
• W2118771330 creator A5081326206 @default.
• W2118771330 creator A5091318797 @default.
• W2118771330 date "2009-03-01" @default.
• W2118771330 modified "2023-10-10" @default.
• W2118771330 title "Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study" @default.
• W2118771330 cites W1556454749 @default.
• W2118771330 cites W1711791220 @default.
• W2118771330 cites W187238933 @default.
• W2118771330 cites W1971935548 @default.
• W2118771330 cites W1995900951 @default.
• W2118771330 cites W1996919750 @default.
• W2118771330 cites W2017394727 @default.
• W2118771330 cites W2019779426 @default.
• W2118771330 cites W2020151485 @default.
• W2118771330 cites W2029573304 @default.
• W2118771330 cites W2037179719 @default.
• W2118771330 cites W2046988509 @default.
• W2118771330 cites W2058821053 @default.
• W2118771330 cites W2061862949 @default.
• W2118771330 cites W2063823548 @default.
• W2118771330 cites W2068556430 @default.
• W2118771330 cites W2077183730 @default.
• W2118771330 cites W2094044442 @default.
• W2118771330 cites W2106584820 @default.
• W2118771330 cites W2114395467 @default.
• W2118771330 cites W2117291755 @default.
• W2118771330 cites W2132027522 @default.
• W2118771330 cites W2159507916 @default.
• W2118771330 cites W2163583950 @default.
• W2118771330 cites W2580835465 @default.
• W2118771330 cites W2915779718 @default.
• W2118771330 cites W4211237179 @default.
• W2118771330 cites W4242589154 @default.
• W2118771330 cites W4251062699 @default.
• W2118771330 cites W4253916874 @default.
• W2118771330 cites W4293241248 @default.
• W2118771330 cites W4376595466 @default.
• W2118771330 doi "https://doi.org/10.1016/s1470-2045(09)70003-8" @default.
• W2118771330 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4086808" @default.
• W2118771330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19230772" @default.
• W2118771330 hasPublicationYear "2009" @default.
• W2118771330 type Work @default.
• W2118771330 sameAs 2118771330 @default.
• W2118771330 citedByCount "2239" @default.
• W2118771330 countsByYear W21187713302012 @default.
• W2118771330 countsByYear W21187713302013 @default.
• W2118771330 countsByYear W21187713302014 @default.
• W2118771330 countsByYear W21187713302015 @default.
• W2118771330 countsByYear W21187713302016 @default.
• W2118771330 countsByYear W21187713302017 @default.
• W2118771330 countsByYear W21187713302018 @default.
• W2118771330 countsByYear W21187713302019 @default.
• W2118771330 countsByYear W21187713302020 @default.
• W2118771330 countsByYear W21187713302021 @default.
• W2118771330 countsByYear W21187713302022 @default.
• W2118771330 countsByYear W21187713302023 @default.
• W2118771330 crossrefType "journal-article" @default.
• W2118771330 hasAuthorship W2118771330A5000921376 @default.
• W2118771330 hasAuthorship W2118771330A5014838075 @default.
• W2118771330 hasAuthorship W2118771330A5015991333 @default.
• W2118771330 hasAuthorship W2118771330A5031248010 @default.
• W2118771330 hasAuthorship W2118771330A5032585809 @default.
• W2118771330 hasAuthorship W2118771330A5040454560 @default.
• W2118771330 hasAuthorship W2118771330A5042018798 @default.
• W2118771330 hasAuthorship W2118771330A5042020284 @default.
• W2118771330 hasAuthorship W2118771330A5043227502 @default.
• W2118771330 hasAuthorship W2118771330A5046816795 @default.
• W2118771330 hasAuthorship W2118771330A5052920087 @default.
• W2118771330 hasAuthorship W2118771330A5053367608 @default.
• W2118771330 hasAuthorship W2118771330A5063557220 @default.
• W2118771330 hasAuthorship W2118771330A5065716888 @default.
• W2118771330 hasAuthorship W2118771330A5065804627 @default.
• W2118771330 hasAuthorship W2118771330A5070851212 @default.
• W2118771330 hasAuthorship W2118771330A5071026405 @default.
• W2118771330 hasAuthorship W2118771330A5081326206 @default.
• W2118771330 hasAuthorship W2118771330A5091318797 @default.
• W2118771330 hasBestOaLocation W21187713302 @default.
• W2118771330 hasConcept C104317684 @default.
• W2118771330 hasConcept C126322002 @default.

• next